PD0325901|MEK inhibitor|CAS# 391210-10-9

Home >> Signaling Pathways >> MAPK Signaling >> MEK1/2 >> PD0325901

Size	Price	Stock
10mM (in 1mL DMSO)	$55.00	In stock
5mg	$45.00	In stock
25mg	$150.00	In stock
100mg	$360.00	In stock
500mg	$980.00	In stock

Publications citing ApexBio Products

Nature.
2016 Apr 21;532(7599):398-401.

Nature.
2015 Aug 20;524(7565):309-14.

Cell.
2015 Aug 27;162(5):987-1002.

Cell.
2015 Feb 12;160(4):729-44.

Immunity.
2016 Jan 19;44(1):88-102

Nat Cell Biol.
2015 May;17(5):627-38.

Nat Neurosci.
2015 Oct;18(10):1464-73.

Nat Commun.
2016 Feb 1;7:10492.

J Cell Biol.
2016 Apr 11;213(1):109-25.

Cell Host Microbe.
2016 Jul 13;20(1):13-24.

Proc Natl Acad Sci U S A.
2016 Mar 8;113(10):2585-90.

Proc Natl Acad Sci U S A.
2015 Jun 30;112(26):E3365-73.

Proc Natl Acad Sci U S A.
2015 Jul 28;112(30):9412-7.

Autophagy.
2016 Jul 2;12(7):1129-52.

Cancer Res canres.
2946.2015.

Elife.
2016 Jan 14;5. pii: e12203.

Nucleic Acids Res.
2016 Feb 18;44(3):e2.

EMBO Rep.
2015 Sep;16(9):1114-30.

Oncogene.
2016 Mar 21.

Cell Rep.
2015 Sep 29;12(12):1986-96.

Cell Death Differ.
2016 Jun;23(6):1026-37.

Cell Death Differ.
2016 Jan;23(1):76-88.

Diabetes Obes Metab.
2015 Apr;17(4):403-13.

Oncotarget.
2015 Jan 20;6(2):1171-89.

J Neurosci.
2015 Sep 23;35(38):13244-56.

Sci Signal.
2014 Dec 23;7(357):ra122.

Mol Ther.
2015 Sep;23(9):1475-85.

J Nucl Med.
2016 Feb;57 Suppl 1:75S-80S.

Cardiovasc Res.
2015 Apr 1;106(1):153-62.

Cell Mol Life Sci.
2015 Nov;72(22):4399-407.

Anal Chem.
2015;87(10):5046-9.

Cancer Lett.
2016 Apr 28;374(1):1-11.

Quality Control

Quality Control & MSDS

View current batch:

Purity = 99.64%

Chemical structure

Related Biological Data

Inhibition of the PI3K and MEK-ERK pathway enhances cell death in HCT116 cells. HCT116 cells stably transduced with control or PIK3CA inducible shRNA were treated with PD0325901 in the presence or absence of doxycycline. HCT116 cells grown in the presence or absence of doxycycline were treated with PD0325901 for 48 h. Cells were subsequently fixed with formaldehyde and stained with Hoechst 33342 to visualize fragmented nuclei. For each treatment condition, 1,500 cells were counted under a fluorescence microscope.

Biological Activity

Targets
IC50

Protocol

Cell experiment: [1]
Cell lines	M14 (BRAFV600E) cells
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Reacting condition	1 μM, 48 hours for cell cycle accumulation ≥100 nM, 72 hours for DNA decrease
Applications	PD0325901 caused a dose- and time-dependent cell cycle accumulation at the G1/S boundary and depletion of cells in the S-phase. It also caused a dose- and time-dependent increase in the percentage of cellswith sub-G1 DNA content, thus indicating induction of apoptosis. Compared with the kinetics and dose-response curve of cell cycle inhibition, DNA decrease to sub-G1 levels required longer times of exposure (72 hours) and higher concentrations of the drug (≥100 nM).
Animal experiment: [1]
Animal models	Female CD-1 nude (nu/nu) mice injected with M14 (BRAFV600E) and ME8959 (wtBRAF) cells
Dosage form	Oral administration, 50 mg/kg per day for 21 days
Application	Daily oral treatment of established tumors with 50 mg/kg per day of PD0325901 significantly impaired in vivo tumor growth (60%-65% inhibition compared with controls at the end of a 21-day treatment cycle) in both M14 and ME8959 xenografts. The effects of PD0325901 were reversible, and tumors grew back after treatment interruption.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1] Ciuffreda L, Del Bufalo D, Desideri M, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia, 2009, 11(8): 720-W6.

PD0325901 Dilution Calculator

calculate

PD0325901 Molarity Calculator

calculate

Chemical Properties

Cas No.	391210-10-9	SDF	Download SDF
Synonyms	PD0325901,PD-0325901,PD 0325901,PD325901,PD 325901,PD-325901
Chemical Name	N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
Canonical SMILES	C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O
Formula	C₁₆H₁₄F₃IN₂O₄	M.Wt	482.19
Solubility	Soluble in DMSO > 10 mM	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

Research Update

1. Modulation of endochondral ossification by MEK inhibitors PD 0325901 and AZD6244 (Selumetinib). Bone. 2014 Feb;59:151-61. doi: 10.1016/j.bone.2013.11.013. Epub 2013 Nov 20.
Abstract
PD 0325901, a MEKi, affects chondrocyte hypertrophy, matrix resorption, fracture healing and bone architecture, where it expands the hypertrophic zone of th growth plate and reduces osteoclast surface systemically.

2. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901. Mol Cancer Ther. 2012 Oct;11(10):2274-83. doi: 10.1158/1535-7163.MCT-11-0984. Epub 2012 Jul 2.
Abstract
The MEK inhibitor PD-0325901 prevented PF-04880594-induced hyperplasia and ERK hyperphosphorylation at clinically well-tolerated doses.

3. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011 Aug;68(2):547-52. doi: 10.1007/s00280-011-1620-1. Epub 2011 Apr 24.
Abstract
The tolerability and antitumor activity of PD-0325901 have been assessed in cancer patients.

4. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1968-76. doi: 10.1158/1535-7163.MCT-10-0062. Epub 2010 Jun 29.
Abstract
PD0325901, a MEK1/2 inhibitor, is an effective drug for the treatment of thyroid cancers with RET/PTC or BRAF mutation, where PTC cells with a BRAF mutation is more sensitive to PD0325901 than PTC cells with RET/PTC1 rearrangement.

5. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology. 2010 Apr;51(4):1218-25. doi: 10.1002/hep.23470.
Abstract
PD0325901, a MEK inhibitor with possible inhibitory effects against HCC tumorigenesis, inhibited tumor growth and MEK activity in various HCC cells and HCC mouse models.

Background

PD0325901 is a specific inhibitor of mitogen-activated protein kinase MEK. PD0325901 is a small molecular with the formula of C₁₆H₁₄F₃IN₂O₄ and Molecular Weight of 482. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, and MEK/ERK regulates cell proliferation, survival, and differentiation in response to extracellular signals. PD0325901 effectively reduces P-ERK levels and cell growth in vitro, and inhibits tumor growth in mouse model in vivo

References:
1. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. J Leyton, G Smith, M Lees, M Peruma. Molecular cancer Therapeutics. 2008
2. Targeting mitogen‐activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model. M Hennig, MT Yip‐Schneider, S Wentz, H Wu. Hepatology. 2010